Inhalable Formulation of a Solution Containing Glycopyrronium Bromide
AssigneeCai Gu Huang
InventorsCai Gu Huang, Lu Lu Zhang
Life of this patent
Estimating the term…
Abstract
The present invention discloses a liquid pharmaceutical formulation and a method for administering the liquid pharmaceutical formulation by nebulizing the pharmaceutical formulation in an inhaler. The propellant-free pharmaceutical formulation comprises: (a) glycopyrronium bromide or a salt thereof; (b) a pharmacologically acceptable preservative, (c) a pharmacologically acceptable stabilizer, (d) a solvent, (e) a pH adjusting agent, and optionally (f) other pharmaceutically acceptable additives.
Claims18
A liquid, propellant-free pharmaceutical formulation comprising:
- (a) glycopyrronium or a salt thereof present in an amount between about 10 mg/100 ml and about 500 mg/100 ml;
- (b) water;
- (c) a pharmacologically acceptable stabilizer;
- and (d) a pharmacologically acceptable preservative, wherein the pharmaceutical formulation has a pH in a range from about 2.0 to about 6.0, and wherein the formulation is administered using a soft mist inhaler.
A device for administering glycopyrronium or a salt thereof comprising:
- (a) a soft mist inhaler and
- (b) a liquid, propellant-free pharmaceutical formulation comprising:
- (i) glycopyrronium or a salt thereof present in an amount between about 20 mg/100 ml and about 500 mg/100 ml;
- (ii) water;
- (iii) a pharmacologically acceptable stabilizer;
- and
- (iv) a pharmacologically acceptable preservative,
- wherein the pharmaceutical formulation has a pH in a range from about 2.0 to about 6.0, and
- wherein the formulation is contained in the soft mist inhaler.
Dependencies are inferred from the claim text.